News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Subscribe To Our Newsletter & Stay Updated
